• 1. Which of the following statements best describes the state of fluid biomarkers in MS?*
  • 2. Which of the following statements about CAR-T therapy is not true?*
  • 3. The phase II EMBOLD trial failed. What did it test?*
  • 4. Which of the following types of machine learning models underlies generative artificial intelligence, like ChatGPT?*
  • 5. Which of the following MS diagnostic imaging markers requires susceptibility-sensitive MRI?*
  • 6. Which of the following Anti-CD20 mAbs is a glycoengineered chimeric mAb?*
  • 7. Tolebrutinib, a brain penetrant BTK inhibitor, was shown to delay the onset of disability progression in patients with:*

  • EVALUATION FORM

  • AcademicCME appreciates your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs. Learners must complete this evaluation form to receive acknowledgement for completing this activity.

  • What is your license?*

  • Please rate the extent to which this activity met the following objectives:

  • Learning Objectives
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • This educational activity will result in a change in my practice behavior.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
  • Date
     - -
    2 digit month, 2 digit day, 4 digit year

  • Attestation to time spent on activity: AcademicCME designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™, 10.0 CNE Contact Hours (Provider #P0491) or 10.0 CPE Contact Hours for participation in the full educational activity.

  • Please select your credit type from the below:

  • AcademicCME thanks you for your participation in this activity. 

    All information provided improves the scope and purpose of our programs.

  • Should be Empty: